Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from ImmunityBio ( (IBRX) ) is now available.
On December 10, 2025, ImmunityBio, Inc. appointed Bruce Wendel to its Board of Directors, effective December 12, 2025, with his term expiring at the 2026 annual stockholders meeting. Wendel, recognized as an independent director, brings extensive experience from his previous roles in the pharmaceutical industry, including leadership positions at ProMetic Biosciences Ltd. and Hepalink USA. His appointment is expected to strengthen ImmunityBio’s strategic direction and industry positioning.
The most recent analyst rating on (IBRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
ImmunityBio’s overall stock score is driven by its strong corporate event with the EMA nod for ANKTIVA®, which boosts its market potential. However, financial instability and valuation concerns due to ongoing losses and negative equity weigh heavily on the score. Technical indicators show neutral momentum, providing neither a strong positive nor negative influence.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio, Inc. operates in the biotechnology sector, focusing on developing innovative therapies to treat cancer and infectious diseases. The company is known for its work on immunotherapy and cell-based treatments, aiming to address unmet medical needs in these areas.
Average Trading Volume: 10,077,592
Technical Sentiment Signal: Sell
Current Market Cap: $2.32B
See more insights into IBRX stock on TipRanks’ Stock Analysis page.